What is the mechanism of action of Ingrezza? A pharmacological deep dive
•
2 min read
Ingrezza (valbenazine) was the first medication specifically approved by the FDA for the treatment of tardive dyskinesia (TD), a challenging involuntary movement disorder. The answer to what is the mechanism of action of Ingrezza lies in its selective inhibition of a crucial protein in the brain's dopamine pathway. This targeted approach helps to normalize nerve signaling that has gone awry.
